What is OptiDerma & Opal A? OptiDerma is a moisturising product that contains the active bio- pharmacueutical OPAL A. OPAL A is derived from the inner flesh of the Carica Papaya fruit. Has shown to be: * Anti-inflammatory (papain) * Vasoactive (NA, Nitric oxide) * Proteolytic (papain) * Antibacterial/antioxidant activity Improves skin integrity & healing environment. The use of OptiDerma Moisturising Skin Support has clearly shown positive results in promoting skin integrity, peripheral circulation and wound care outcomes. History of Health Focus Products Australia (HFPA) Phoenix Eagle originally developed a set of topically applied products (OPAL products) that appeared to have remarkable wound-healing and other therapeutic properties. The OPAL products were derived from fruits and vegetable that were subjected to a patented process (the OPAL process), which involved the addition of a simple natural compound and caused a chemical reaction to occur in the fruit and vegetable pulp. The OPAL process, which essentially is a novel fruit and plant extract alkalisation process, began to receive attention from medical academia within Australia and internationally. A publication in the peer-reviewed journal, Wound Practice and Research suggested clinical and health-economic benefits of OPAL products. Publication of an abstract at a peer-reviewed conference of the Australian Wound Management Association, by Associate Professor Geoff Mitchell of the Queensland University, reported on a number of anecdotal cases where OPAL products were of great therapeutic benefit in wound healing. The OPAL process represented a platform technology that has lead to many products and applications across multiple markets. It is this technology and these many product applications that HFPA has developed and marketed within Australia. HFPA Chairman Dr Mark Baldock became aware of Phoenix Eagle and the OPAL process in 2006 and became an initial investor in the company. He could see the benefits of a novel wound healing product to address the recognised epidemic of diabetic related venous ulcers and other wound complications related to the ageing population.